Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of SHR6508 in Secondary Hyperparathyroidism
NCT06877247Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR6508 in secondary hyperparathyroidism (SHPT), sponsored by Hengrui Therapeutics. Primary endpoints: Cumulative excretion of radioactivity and Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure. Started Dec 2024; status: completed.
02
Drugs
SHR6508
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT06877247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06877247.